Otherwise, CDH1 showed a variety of alterations, but most notably was amplified in NEPC (3.5%) and deleted in primary tumors and in metastatic PC (0.5%–4.5%) (Figure 3A and Table S5). This evidence concerns the gene CDH1 and pachyonychia congenita.